IMMUNEONCO-B (01541) has announced a significant financial transaction. On June 17, 2026, the company entered into an agreement to subscribe for a financial product from Vital Ventures, with a total value of HK$87.5 million. This subscription, known as the Vital Subscription Product, will be funded entirely from the group's existing internal cash reserves and surplus funds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.